Intelligent Bio Solutions Q3 revenue up 80% to $0.82M; cash $9.4M after $10.76M capital raise

INTELLIGENT BIO SOLUTIONS INC.

2024-Q3 EPS reported -$6.64 vs consensus -$5.41 ▼ miss (-22.8%)

Revenue of $0.82M for Q3 FY2024, up 80% YoY; nine-month revenue $2.38M, up 193%.
Net loss for Q3 was $2.98M, including $0.54M non-cash items; nine-month net loss decreased to $7.37M.
Cash and equivalents $9.4M as of March 31, 2024, up from $1.1M at Dec 31, 2023, after net capital raise of ~$10.76M.
FDA 510(k) clinical studies with Cliantha Research underway; submission expected by end of 2024, US entry planned in 2025.
Secured 26 new accounts during quarter, representing ~16,779 employees; European patent granted for DSR-Plus Cartridge Reader.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTELLIGENT BIO SOLUTIONS INC. reported nine months ended March 31, 2024 results: revenue $2.38 million, net income $7.37 million.

Period: nine months ended March 31, 2024
Revenue: $2.38 million
Net income: $7.37 million
Result: reported results

Exact text from the filing

Total revenue for the nine months ended March 2024 was $2.38 million, an increase of 193% compared to the same period the year prior.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2024 results: revenue $0.82 million, net income $2.98 million.

Period: fiscal third quarter ended March 31, 2024
Revenue: $0.82 million
Net income: $2.98 million
Result: reported results

Exact text from the filing

Total revenues for the fiscal third quarter were $0.82 million, an increase of 80% compared to the same period the year prior.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-018242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.